Redefining Medicine by Transforming Expression

At Syros, we are advancing a new wave of medicines to control the expression of disease-driving genes. The genes expressed – turned on, off, up or down – in any given cell determine its type and function. Because gene expression is fundamental to all cells, we believe our pioneering approach has potential to lead to better medicines for patients with a range of diseases that have largely eluded other genomics-based approaches. At the heart of all our efforts is our dedication to making a profound difference for patients and their families.

Learn More About Gene Control

View Video

Our Pioneering Approach

Rooted in a deep understanding of how the expression of genes is controlled, our approach represents a new and unexploited field for drug discovery and development. Targeted drug discovery to date has focused largely on inhibiting or otherwise changing the function of abnormal genes and proteins. But many more diseases could be treated by controlling the expression of both abnormal and normal genes, turning them on, off, up or down. Until recently, however, scientists have lacked the tools to study the regulatory regions of the genome that control the expression of genes.

We are now at a pivotal point in time where a confluence of scientific and technological advances is bringing into view what was once beyond our reach. Building on the seminal work of our scientific founders, we have built the first platform dedicated to systematically and efficiently analyzing regulatory regions of the genome to identify disease-causing alterations in gene expression and develop medicines to control the expression of genes critical to a given cell.

Our Growing Pipeline

We are advancing a robust product pipeline based on this pioneering approach. Our lead programs are SY-1425, a first-in-class selective retinoid acid receptor alpha (RARα) agonist that we are investigating as both a monotherapy and a combination agent in a Phase 2 clinical trial in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and SY-1365, a first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor in a Phase 1 clinical trial in patients with transcriptionally dependent solid tumors, including triple negative breast, small cell lung and ovarian cancers. We also have multiple programs in earlier stages of research and development in oncology, including immuno-oncology, autoimmune disorders and genetic diseases.

View Programs

How Gene Control Can Redefine Medicine

Because gene expression is fundamental to the function of all cells, we believe our pioneering approach has broad potential to lead to medicines that provide a profound and durable benefit for patients with a range of diseases that have largely eluded other genomics-based approaches.

View Platform

New Drug Targets for Array of Disease

Identify a wide array of new drug targets that are not identifiable through other genomics-based approaches across a range of diseases.

Unique Lens for Segmenting Patients

Provide a new lens for diagnosing and segmenting patients based on the specific makeup of their disease, including patients with complex, multi-factorial diseases that have eluded segmentation to date with other genomics-based approaches.

Influences Multiple Disease Drivers

Advance a new wave of medicines that influence multiple disease-driving genes through a single target, making them less susceptible to the development of drug resistance and potentially providing patients with a more profound and durable benefit than many of today’s therapies.